Pfizer (PFE) is collaborating with Atavistik Bio to accelerate the discovery of new precision allosteric therapeutics, Atavistik said Thursday.
Financial terms of the partnership were not disclosed.
Under the research partnership, the companies will use Atavistik's AMPS platform to identify allosteric binders against two undisclosed targets picked by Pfizer, according to Atavistik.
The collaboration grants Pfizer the option to license the programs at the end of the research period, Atavistik added.
Price: 26.61, Change: +0.08, Percent Change: +0.30
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。